Keyphrases
Metastatic Melanoma
100%
Vemurafenib
100%
BRAF V600E mutation
40%
BRAFV600
40%
Clinical Trials
20%
Clinical Application
20%
Highly Selective
20%
Treatment Strategy
20%
Targeted Therapy
20%
Squamous Cell Cancer
20%
Low Toxicity
20%
Tumor Response
20%
Protein Signaling Pathways
20%
Drug Resistance
20%
Improved Outcomes
20%
Adverse Effects
20%
Melanoma Patients
20%
Melanoma
20%
Area Cover
20%
Development Result
20%
Squamous Cell Carcinoma (SqCC)
20%
Novel Therapeutics
20%
Chemotherapy Resistance
20%
Combination Therapy
20%
Response-outcome
20%
FDA-approved Drugs
20%
Precision Medicine
20%
Preclinical Data
20%
Expert Opinion
20%
Additional Treatment
20%
New Combination
20%
Toxicity Profile
20%
Phase III Clinical Trial
20%
Cutaneous Squamous Cell Carcinoma (cSCC)
20%
Cancer Clinical Trials
20%
Combination Trials
20%
Phase 1/2 Clinical Trial
20%
Drug Screen
20%
Paradoxical Activation
20%
Medicine and Dentistry
Metastatic Melanoma
100%
Vemurafenib
100%
Nodular Melanoma
40%
Clinical Trial
40%
Neoplasm
20%
Mitogen-Activated Protein Kinase
20%
Signal Transduction
20%
Cancer Cell
20%
Combination Therapy
20%
Personalized Medicine
20%
Squamous Cell Carcinoma
20%
Targeted Therapy
20%
Adverse Event
20%
Squamous Cell
20%
Drug Resistance
20%
Skin Carcinoma
20%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Vemurafenib
100%
Clinical Trial
40%
Squamous Cell Carcinoma
40%
Melanoma
40%
Neoplasm
20%
Combination Therapy
20%
Drug Resistance
20%
Adverse Event
20%
Skin Carcinoma
20%